September 18, 2019
A Pennsylvania federal judge voiced doubt on Wednesday that antitrust claims by Endo Pharmaceuticals shareholders were suitable for a jury, saying the allegations of parallel price increases among the company and its competitors are contrary to economics.
October 29, 2018
A proposed class of Endo Pharmaceuticals shareholders has asked a Pennsylvania federal judge to reject the company's bid to dismiss a suit claiming the drugmaker inflated stock prices by concealing a conspiracy to fix the prices of generic drugs.
June 20, 2018
A Pennsylvania federal judge appointed Bleichmar Fonti & Auld LLP as lead counsel in Endo International PLC shareholders' suit claiming the company concealed knowledge of alleged price-fixing by Par Pharmaceutical Holdings Inc. before acquiring the business, finding Tuesday that the firm's client was best suited to lead the proposed class action.
November 15, 2017
Endo International PLC shareholders hit the drugmaker with a proposed class action Tuesday in Pennsylvania federal court claiming it didn't properly disclose that Par Pharmaceutical Holdings Inc., which the company acquired in 2015, has allegedly colluded to fix generic-drug prices.